98%
921
2 minutes
20
Background: This study aimed to assess the clinical characteristics, management strategies, and outcomes of ocular and adnexal injuries caused by animal attacks.
Methods: A retrospective analysis was conducted on patients hospitalized for animal-induced eye injuries at the Eye and ENT Hospital of Fudan University (2003-2023). This study was approved by the Ethics Committee of the Eye and ENT Hospital of Fudan University (Ref. No. 2024146, August 2024). Informed consent was waived. The study complied with the Declaration of Helsinki. Clinical presentations, treatment approaches, and outcomes were systematically reviewed.
Results: Sixteen patients with ocular injuries from animal attacks were included, with 75.0% being male ( < 0.05) and a median age of 13.5 years (range: 2-69 years). Injuries were most commonly caused by birds (5 cases), followed by dogs (4), cats (2), fish (2), wasps (2), and bees (1). Most injuries occurred during attempts to approach or interact with the animals. Corneal injury was most frequent (12 cases, < 0.05), followed by eyelid and canalicular lacerations, cataracts, endophthalmitis, retinal detachment, globe rupture, penetrating ocular injuries, and orbital fractures. Treatments started on average 4.03 ± 4.98 days post-injury. Surgeries included eyelid/canalicular repair, globe reconstruction, lens extraction, and pars plana vitrectomy (PPV). Cataracts ( < 0.05) and retinal detachment ( ≤ 0.01) were linked to poorer initial visual acuity (LogMAR). Post-treatment VA improved significantly, from 2.4 to 0.19 ( ≤ 0.01), especially in lens surgery patients ( < 0.05).
Conclusions: Animal-induced ocular and adnexal injuries predominantly affect males and may cause irreversible visual impairment. Cataracts and retinal detachment predict poor initial vision. Early diagnosis and timely surgery, especially lens surgery, are essential for recovery. Public education and prevention are essential to reduce such injuries.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12308878 | PMC |
http://dx.doi.org/10.1080/07853890.2025.2537915 | DOI Listing |
Eur J Cardiothorac Surg
September 2025
Department of Cardiovascular Surgery, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka-shi, Saitama, 350-1298, Japan.
Objectives: Coronary artery bypass grafting (CABG) using bilateral internal thoracic artery (BITA) conduits can achieve good outcomes for multivessel lesions. This study evaluated early angiographic patency and outcomes following off-pump CABG (OPCAB) using only in situ BITA and right gastroepiploic artery (rGEA) grafts.
Methods: This retrospective analysis included patients undergoing OPCAB using only in situ skeletonized BITA and rGEA grafts (July 2007 to March 2019).
Interv Neuroradiol
September 2025
Department of Neuroradiology, Walton Centre for Neurology and Neurosurgery, Liverpool, UK.
ObjectiveThis study aims to determine the outcomes of nickel allergic patients who underwent a trial of forearm arterial stenting with a nickel-based stent, with follow-up to assess for an allergic reaction. In the absence of adverse effects, patients had their intracranial aneurysm treatment with a nickel-based cerebrovascular device.MethodsA retrospective analysis was performed on patients who had an allergy to nickel, with an intracranial aneurysm who underwent treatment with a permanently implanted nickel-containing device.
View Article and Find Full Text PDFJAMA Netw Open
September 2025
Division of Cardiology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei, Taiwan.
Importance: The cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may vary by body mass index (BMI), but evidence on BMI-specific outcomes remains limited.
Objective: To investigate the associations of GLP-1 RA use with cardiovascular and kidney outcomes across BMI categories in patients with type 2 diabetes.
Design, Setting, And Participants: This retrospective cohort study used the Chang Gung Research Database, a clinical dataset covering multiple hospitals in Taiwan.
Oncologist
September 2025
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Background: Belzutifan is a HIF-2ɑ inhibitor approved for the treatment of tumors in von Hippel-Lindau (VHL) syndrome and sporadic metastatic clear cell renal cell carcinoma (spRCC) in the refractory setting. The efficacy and side effects of belzutifan are well-documented from clinical trials, however, real-world data examining the incidence and management of adverse events (AEs) are lacking. Our study aims to describe the AE profiles of belzutifan in spRCC and VHL populations.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
September 2025
Medical School, Laboratory of Genetics and Molecular Pathology, University Hassan II, Casablanca, Morocco.
In-stent restenosis remains a significant challenge in interventional cardiology despite technological advancements. This retrospective case-control study conducted at the University Hospital Center Ibn Rochd in Casablanca (2020-2023) examined risk factors associated with coronary in-stent restenosis in 68 patients equally distributed between restenosis and no-restenosis groups. Diabetes emerged as a powerful predictor of restenosis (RR=4.
View Article and Find Full Text PDF